MCRPC (metastatic castration-resistant prostate cancer)

Clinical trials for MCRPC (metastatic castration-resistant prostate cancer) explained in plain language.

Never miss a new study

Get alerted when new MCRPC (metastatic castration-resistant prostate cancer) trials appear

Sign up with your email to follow new studies for MCRPC (metastatic castration-resistant prostate cancer), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 11 Not yet recruiting 1

New hope for prostate cancer: drug combo aims to delay tumor growth

Disease control Not yet recruiting

This study tests a daily pill called zanzalintinib in men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Pluvicto. The goal is to see if the drug can delay cancer growth or shrinkage. About 30 participants will take …

Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)

Phase 2 • Sponsor: Stuthi Perimbeti • Aim: Disease control

Last updated Jun 27, 2026 13:02 UTC

MCRPC (metastatic castration-resistant prostate cancer)

Get alerted when new MCRPC (metastatic castration-resistant prostate cancer) trials appear

New hope for prostate cancer: drug combo aims to delay tumor growth